gsk692342
Vaccineexperimental
Clinical trial activity
11 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
10
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2004 (NCT00730795)
Timeline
Indications
Mechanism of action
- Mycobacterium tuberculosisImmunity, active
Mycobacterium tuberculosis immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gsk692342
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01755598 | Phase 2 | Aug 19, 2014 | Aeras, GlaxoSmithKline |
| NCT01669096 | Phase 2 | Aug 1, 2012 | Aeras, GlaxoSmithKline |
| NCT01424501 | Phase 2 | Nov 1, 2011 | GlaxoSmithKline |
| NCT01262976 | Phase 2 | Jan 1, 2011 | GlaxoSmithKline |
| NCT01098474 | Phase 2 | Jul 1, 2010 | Aeras, GlaxoSmithKline |
| NCT00950612 | Phase 2 | Dec 1, 2009 | Aeras, GlaxoSmithKline |
| NCT00707967 | Phase 2 | Jun 1, 2008 | GlaxoSmithKline |
| NCT00621322 | Phase 2 | Apr 1, 2008 | GlaxoSmithKline |
| NCT00600782 | Phase 2 | Feb 1, 2008 | GlaxoSmithKline |
| NCT00397943 | Phase 2 | Nov 1, 2006 | GlaxoSmithKline |
| NCT00730795 | Phase 1 | Jan 1, 2004 | Corixa, GlaxoSmithKline |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 11 | 11 | 2 | 2004 |
| Aeras | Academic/Hospital | 4 | 0 | 1 | 2009 |
| Corixa | For profit | 1 | 0 | 1 | 2004 |
3 organizations
Page 1 / 1